Recent Finacing
Recent Raise
Calluna Pharma, formed by merging Oxitope and Arxx, develops selective monoclonal antibodies targeting DAMPs to treat acute/chronic inflammation and tissue fibrosis; programs include CAL101 (anti‑S100A4) and CAL102.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Calluna Pharma.
